JULIE RUBINSTEIN - 03 Mar 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
President and COO
Signature
/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact
Issuer symbol
ADPT
Transactions as of
03 Mar 2026
Net transactions value
-$1,493,428
Form type
4
Filing time
05 Mar 2026, 19:42:57 UTC
Previous filing
06 Mar 2025
Next filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RUBINSTEIN JULIE President and COO C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE /s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact 05 Mar 2026 0001780664

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise +14,722 +2.5% $6.55* 602,971 03 Mar 2026 Direct F1
transaction ADPT Common Stock Options Exercise +11,881 +2% $12.14* 614,852 03 Mar 2026 Direct F1
transaction ADPT Common Stock Sale $378,312 -24,423 -4% $15.49 590,429 03 Mar 2026 Direct F1, F2
transaction ADPT Common Stock Sale $106,439 -6,518 -1.1% $16.33 583,911 03 Mar 2026 Direct F1, F3
transaction ADPT Common Stock Options Exercise +14,722 +2.5% $6.55* 598,633 04 Mar 2026 Direct F1
transaction ADPT Common Stock Options Exercise +11,881 +2% $12.14* 610,514 04 Mar 2026 Direct F1
transaction ADPT Common Stock Sale $513,621 -30,941 -5.1% $16.60 579,573 04 Mar 2026 Direct F1, F4
transaction ADPT Common Stock Options Exercise +14,722 +2.5% $6.55* 594,295 05 Mar 2026 Direct F1
transaction ADPT Common Stock Options Exercise +11,881 +2% $12.14* 606,176 05 Mar 2026 Direct F1
transaction ADPT Common Stock Sale $495,056 -30,941 -5.1% $16.00 575,235 05 Mar 2026 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (right to buy) Options Exercise -14,722 -7.5% $0.000000* 180,603 03 Mar 2026 Common Stock 14,722 $6.55 Direct F1, F6
transaction ADPT Stock Option (right to buy) Options Exercise -11,881 -2.6% $0.000000* 451,463 03 Mar 2026 Common Stock 11,881 $12.14 Direct F1, F7
transaction ADPT Stock Option (right to buy) Options Exercise -14,722 -8.2% $0.000000* 165,881 04 Mar 2026 Common Stock 14,722 $6.55 Direct F1, F6
transaction ADPT Stock Option (right to buy) Options Exercise -11,881 -2.6% $0.000000* 439,582 04 Mar 2026 Common Stock 11,881 $12.14 Direct F1, F6
transaction ADPT Stock Option (right to buy) Options Exercise -14,722 -8.9% $0.000000* 151,159 05 Mar 2026 Common Stock 14,722 $6.55 Direct F1, F6
transaction ADPT Stock Option (right to buy) Options Exercise -11,881 -2.7% $0.000000* 427,701 05 Mar 2026 Common Stock 11,881 $12.14 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $16.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.11 to $16.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 to $16.94, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.74 to $16.30, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6 The option is fully vested and exercisable.
F7 The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.